← Back to Search

PARP Inhibitor

18F-FluorThanatrace Imaging for Glioblastoma

Q: Are enrollment opportunities available for this research project?

<p>Affirmative. The relevant information hosted on clinicaltrials.gov demonstrates that this medical study, which was first posted on February 20th 2020, is still in search of members. 12 individuals need to be recruited from a single site.</p>

Q: How many individuals are receiving treatment as part of this trial?

<p>Affirmative. The clinical trial website shows that this investigation, initially posted on February 20th 2020, is actively recruiting participants. They need to find roughly a dozen individuals from 1 medical centre.</p>

Phase < 1

Waitlist Available

Led By Austin R Pantel, MD

Research Sponsored by University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants will have a diagnosis of glioblastoma and be enrolled in the companion treatment trial, IRB 832694.

Participants will be ≥ 22 years of age

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is testing a new brain cancer imaging drug, 18F-Fluorthanatrace, to see if it can be used to find recurrent brain cancer before or after new treatment or surgery.

Who is the study for?

This trial is for adults over 22 with glioblastoma who are also part of a treatment study using TTFields and niraparib. They must understand the research nature of this study, agree to it in writing, and be able to undergo PET/CT scans without issues.Check my eligibility

What is being tested?

The trial tests how well a new radioactive imaging drug called 18F-Fluorthanatrace (18F-FTT) works in detecting recurrent brain cancer when used with PET/CT scanning before or after treatment or surgery.See study design

What are the potential side effects?

Potential side effects aren't specified here but may include reactions related to the injection of the radioactive substance, such as discomfort at the injection site, allergic reactions, or changes due to radiation exposure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have glioblastoma and am enrolled in the IRB 832694 trial.

Select...

I am 22 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Evaluate uptake of [18F]FTT in recurrent glioblastoma after initiation of TTFields therapy.

Secondary outcome measures

Correlate [18F]FTT uptake measures with Homologous recombination deficiency (HRD) status or other markers of "BRCAness".

Trial Design

2Treatment groups

Experimental Treatment

Group I: Surgical candidatesExperimental Treatment1 Intervention

In this arm, subjects who have a clinical indication for surgical resection of the recurrent tumor will receive TTFields therapy for 5-7 days prior to planned surgical resection, undergo resection, and then resume TTFields therapy and initiate niraparib post-operatively.

Group II: Non-surgical candidatesExperimental Treatment1 Intervention

In this arm, subjects that do not have a clinical indication for surgical resection of the recurrent tumor will start TTFields therapy 5-7 days prior to starting oral niraparib (a PARP inhibitor).

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor

2,000 Previous Clinical Trials

42,880,076 Total Patients Enrolled

7 Trials studying Glioblastoma

193 Patients Enrolled for Glioblastoma

Austin R Pantel, MDPrincipal InvestigatorUniversity of Pennsylvania

Media Library

Niraparib (PARP Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04221061 — Phase < 1

Glioblastoma Research Study Groups: Non-surgical candidates, Surgical candidates

Glioblastoma Clinical Trial 2023: Niraparib Highlights & Side Effects. Trial Name: NCT04221061 — Phase < 1

Niraparib (PARP Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04221061 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are enrollment opportunities available for this research project?

"Affirmative. The relevant information hosted on clinicaltrials.gov demonstrates that this medical study, which was first posted on February 20th 2020, is still in search of members. 12 individuals need to be recruited from a single site."

Answered by AI

How many individuals are receiving treatment as part of this trial?

"Affirmative. The clinical trial website shows that this investigation, initially posted on February 20th 2020, is actively recruiting participants. They need to find roughly a dozen individuals from 1 medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

18F-FluorThanatrace (PET/CT) in Glioblastoma

2020. "18F-FluorThanatrace (PET/CT) in Glioblastoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04221061.

All > Glioblastoma New York > Glioblastoma Multiforme